Pinnacle Associates Ltd. Sells 83,972 Shares of Ionis Pharmaceuticals, Inc. (IONS)

Pinnacle Associates Ltd. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 5.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,572,045 shares of the company’s stock after selling 83,972 shares during the period. Ionis Pharmaceuticals accounts for 1.5% of Pinnacle Associates Ltd.’s holdings, making the stock its 8th largest position. Pinnacle Associates Ltd. owned 1.30% of Ionis Pharmaceuticals worth $75,191,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Massey Quick & Co. LLC bought a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $143,000. Teacher Retirement System of Texas boosted its position in shares of Ionis Pharmaceuticals by 31.1% in the second quarter. Teacher Retirement System of Texas now owns 8,577 shares of the company’s stock worth $200,000 after buying an additional 2,036 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in shares of Ionis Pharmaceuticals by 0.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 9,055 shares of the company’s stock worth $211,000 after buying an additional 82 shares during the period. HL Financial Services LLC bought a new position in shares of Ionis Pharmaceuticals during the third quarter worth approximately $216,000. Finally, Numeric Investors LLC bought a new position in shares of Ionis Pharmaceuticals during the second quarter worth approximately $240,000. Institutional investors and hedge funds own 87.76% of the company’s stock.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up 1.48% on Monday, hitting $46.09. The stock had a trading volume of 775,934 shares. The company’s market cap is $5.59 billion. The firm’s 50-day moving average is $46.55 and its 200-day moving average is $38.87. Ionis Pharmaceuticals, Inc. has a 52-week low of $19.59 and a 52-week high of $57.00.

This piece was originally reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international trademark and copyright law. The original version of this piece can be read at http://sleekmoney.com/pinnacle-associates-ltd-sells-83972-shares-of-ionis-pharmaceuticals-inc-ions/1659087.html.

A number of brokerages have recently commented on IONS. BMO Capital Markets lifted their target price on Ionis Pharmaceuticals from $61.00 to $68.00 and gave the stock an “outperform” rating in a report on Wednesday, December 28th. Jefferies Group LLC reiterated a “sell” rating and issued a $17.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, January 6th. Cowen and Company restated a “hold” rating on shares of Ionis Pharmaceuticals in a report on Friday, January 6th. Piper Jaffray Companies restated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, November 9th. Finally, Janney Montgomery Scott restated a “neutral” rating and set a $54.00 price objective (up previously from $50.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, December 28th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $46.09.

In other Ionis Pharmaceuticals news, SVP Patrick R. O’neil sold 1,500 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $46.17, for a total value of $69,255.00. Following the completion of the transaction, the senior vice president now directly owns 12,449 shares of the company’s stock, valued at approximately $574,770.33. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Brett P. Monia sold 2,502 shares of the company’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $46.29, for a total transaction of $115,817.58. Following the completion of the transaction, the senior vice president now directly owns 9,287 shares of the company’s stock, valued at $429,895.23. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,953 shares of company stock valued at $3,845,673. 1.86% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/pinnacle-associates-ltd-sells-83972-shares-of-ionis-pharmaceuticals-inc-ions/1659087.html

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *